Braveheart charges to $382.5M IPO to fund Hengrui cardio drug
Braveheart Bio has priced an upsized $382.5 million IPO to fund a Hengrui-licensed cardiometabolic drug, extending the biotech IPO streak.
Braveheart Bio
Private
Therapeutics for hypertrophic cardiomyopathy and related conditions
Company Info
Recent News
Braveheart pumps more life into biotech IPO market with $382M expected debut
Braveheart pumps more life into biotech IPO market with $382M expected debut
Braveheart Bio targets $1.2 billion valuation in US IPO
Braveheart Bio targets $1.2 billion valuation in US IPO
Braveheart, Attovia join next wave of biotech IPOs
Braveheart, Attovia join next wave of biotech IPOs.
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno.
Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rival
Braveheart files for an IPO to fund Phase 3 of a Hengrui-licensed Cytokinetics rival.
Braveheart files for IPO to support Hengrui-licensed cardio asset
Braveheart files for IPO to support Hengrui-licensed cardio asset
Leadership Team
To be confirmed
Chief Executive Officer
To be confirmed
Chief Medical Officer
To be confirmed
Chief Scientific Officer
Careers & Job Openings